MSD has now agreed two deals around the $10bn mark in 2025 as it looks to shore up its pipeline with Keytruda’s looming ...

Komzifti now becomes the first once-daily targeted therapy for r/r AML, though it will have to fight Syndax’s Revuforj for ...

The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.

Eisai and Biogen have announced UK MHRA approval for Leqembi for intravenous (IV) maintenance dosing to treat early Alzheimer ...

General Proximity has entered a multi-target partnership with Daiichi Sankyo to apply the OmniTAC discovery platform to ...

The “plausible mechanism pathway” will allow personalised drugs to reach the market sooner for patients with genetic diseases ...

The US Food and Drug Administration (FDA) has a new chief drug regulator, with industry veteran Dr Richard Pazdur taking the ...

From e-health records to a biotech hub in Tartu, Estonia is harnessing data, digital infrastructure, and investment to drive ...

Along with the layoffs, the reshuffle includes prioritisation of pipeline assets with the “highest probability of success.” ...

The UK considers raising NICE’s cost-effectiveness threshold, testing the balance between funding innovation and conserving NHS budget.

Chiesi has entered an exclusive licence agreement with Aliada to develop ERTs using BBB-crossing technology for LSDs.

MeiraGTx’s AAV-AIPL1 has already led to vision gains in blind children, as regulatory submissions for the gene therapy close ...